Immunotherapy for gastric cancers

emerging role and future perspectives

Marta Bonotto, Silvio Ken Garattini, Debora Basile, Elena Ongaro, Valentina Fanotto, Monica Cattaneo, Francesco Cortiula, Donatella Iacono, Giovanni Gerardo Cardellino, Nicoletta Pella, Gianpiero Fasola, Lorenzo Antonuzzo, Nicola Silvestris, Giuseppe Aprile

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical development of novel immunotherapies. However, the results of recent trials testing these new agents raise the question on how to identify the patients that could greatly benefit. Areas covered: This article summarizes the current understanding on the biology and the mechanisms underlying different clinical features of gastric cancers. Particularly, after a comprehensive literature search, we speculate whether specific molecular subsets of patients could derive more benefit from immunotherapy. Expert commentary: Most cancers may evade the immune response, which is normally regulated by a delicate balance between activating and inhibitory signals. For example, both CTLA-4 and PD-1, once linked to PD-L1/2, may inhibit T-cell signaling. The use of agent to harness the power of the immune system appears to be the ultimate frontier in gastric cancer treatment. While anti-CTLA-4 antibodies are minimally active, there is growing evidence for the efficacy of PD1/-L1 inhibitors. The search of predictive factors for immunotherapy will provide key hints towards the optimal use of these agents.

Original languageEnglish
Pages (from-to)609-619
Number of pages11
JournalExpert Review of Clinical Pharmacology
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 3 2017

Fingerprint

Immunotherapy
Stomach Neoplasms
Immune System
Neoplasms
Therapeutics
T-Lymphocytes
Drug Therapy
Antibodies

Keywords

  • Gastric cancer
  • immunotherapy
  • molecular classification
  • PD-L1
  • PD-L2

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Immunotherapy for gastric cancers : emerging role and future perspectives. / Bonotto, Marta; Garattini, Silvio Ken; Basile, Debora; Ongaro, Elena; Fanotto, Valentina; Cattaneo, Monica; Cortiula, Francesco; Iacono, Donatella; Cardellino, Giovanni Gerardo; Pella, Nicoletta; Fasola, Gianpiero; Antonuzzo, Lorenzo; Silvestris, Nicola; Aprile, Giuseppe.

In: Expert Review of Clinical Pharmacology, Vol. 10, No. 6, 03.06.2017, p. 609-619.

Research output: Contribution to journalReview article

Bonotto, M, Garattini, SK, Basile, D, Ongaro, E, Fanotto, V, Cattaneo, M, Cortiula, F, Iacono, D, Cardellino, GG, Pella, N, Fasola, G, Antonuzzo, L, Silvestris, N & Aprile, G 2017, 'Immunotherapy for gastric cancers: emerging role and future perspectives', Expert Review of Clinical Pharmacology, vol. 10, no. 6, pp. 609-619. https://doi.org/10.1080/17512433.2017.1313113
Bonotto, Marta ; Garattini, Silvio Ken ; Basile, Debora ; Ongaro, Elena ; Fanotto, Valentina ; Cattaneo, Monica ; Cortiula, Francesco ; Iacono, Donatella ; Cardellino, Giovanni Gerardo ; Pella, Nicoletta ; Fasola, Gianpiero ; Antonuzzo, Lorenzo ; Silvestris, Nicola ; Aprile, Giuseppe. / Immunotherapy for gastric cancers : emerging role and future perspectives. In: Expert Review of Clinical Pharmacology. 2017 ; Vol. 10, No. 6. pp. 609-619.
@article{6203fbea30324c2f9c4bf9f426478ced,
title = "Immunotherapy for gastric cancers: emerging role and future perspectives",
abstract = "Introduction: The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical development of novel immunotherapies. However, the results of recent trials testing these new agents raise the question on how to identify the patients that could greatly benefit. Areas covered: This article summarizes the current understanding on the biology and the mechanisms underlying different clinical features of gastric cancers. Particularly, after a comprehensive literature search, we speculate whether specific molecular subsets of patients could derive more benefit from immunotherapy. Expert commentary: Most cancers may evade the immune response, which is normally regulated by a delicate balance between activating and inhibitory signals. For example, both CTLA-4 and PD-1, once linked to PD-L1/2, may inhibit T-cell signaling. The use of agent to harness the power of the immune system appears to be the ultimate frontier in gastric cancer treatment. While anti-CTLA-4 antibodies are minimally active, there is growing evidence for the efficacy of PD1/-L1 inhibitors. The search of predictive factors for immunotherapy will provide key hints towards the optimal use of these agents.",
keywords = "Gastric cancer, immunotherapy, molecular classification, PD-L1, PD-L2",
author = "Marta Bonotto and Garattini, {Silvio Ken} and Debora Basile and Elena Ongaro and Valentina Fanotto and Monica Cattaneo and Francesco Cortiula and Donatella Iacono and Cardellino, {Giovanni Gerardo} and Nicoletta Pella and Gianpiero Fasola and Lorenzo Antonuzzo and Nicola Silvestris and Giuseppe Aprile",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/17512433.2017.1313113",
language = "English",
volume = "10",
pages = "609--619",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "6",

}

TY - JOUR

T1 - Immunotherapy for gastric cancers

T2 - emerging role and future perspectives

AU - Bonotto, Marta

AU - Garattini, Silvio Ken

AU - Basile, Debora

AU - Ongaro, Elena

AU - Fanotto, Valentina

AU - Cattaneo, Monica

AU - Cortiula, Francesco

AU - Iacono, Donatella

AU - Cardellino, Giovanni Gerardo

AU - Pella, Nicoletta

AU - Fasola, Gianpiero

AU - Antonuzzo, Lorenzo

AU - Silvestris, Nicola

AU - Aprile, Giuseppe

PY - 2017/6/3

Y1 - 2017/6/3

N2 - Introduction: The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical development of novel immunotherapies. However, the results of recent trials testing these new agents raise the question on how to identify the patients that could greatly benefit. Areas covered: This article summarizes the current understanding on the biology and the mechanisms underlying different clinical features of gastric cancers. Particularly, after a comprehensive literature search, we speculate whether specific molecular subsets of patients could derive more benefit from immunotherapy. Expert commentary: Most cancers may evade the immune response, which is normally regulated by a delicate balance between activating and inhibitory signals. For example, both CTLA-4 and PD-1, once linked to PD-L1/2, may inhibit T-cell signaling. The use of agent to harness the power of the immune system appears to be the ultimate frontier in gastric cancer treatment. While anti-CTLA-4 antibodies are minimally active, there is growing evidence for the efficacy of PD1/-L1 inhibitors. The search of predictive factors for immunotherapy will provide key hints towards the optimal use of these agents.

AB - Introduction: The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical development of novel immunotherapies. However, the results of recent trials testing these new agents raise the question on how to identify the patients that could greatly benefit. Areas covered: This article summarizes the current understanding on the biology and the mechanisms underlying different clinical features of gastric cancers. Particularly, after a comprehensive literature search, we speculate whether specific molecular subsets of patients could derive more benefit from immunotherapy. Expert commentary: Most cancers may evade the immune response, which is normally regulated by a delicate balance between activating and inhibitory signals. For example, both CTLA-4 and PD-1, once linked to PD-L1/2, may inhibit T-cell signaling. The use of agent to harness the power of the immune system appears to be the ultimate frontier in gastric cancer treatment. While anti-CTLA-4 antibodies are minimally active, there is growing evidence for the efficacy of PD1/-L1 inhibitors. The search of predictive factors for immunotherapy will provide key hints towards the optimal use of these agents.

KW - Gastric cancer

KW - immunotherapy

KW - molecular classification

KW - PD-L1

KW - PD-L2

UR - http://www.scopus.com/inward/record.url?scp=85019610649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019610649&partnerID=8YFLogxK

U2 - 10.1080/17512433.2017.1313113

DO - 10.1080/17512433.2017.1313113

M3 - Review article

VL - 10

SP - 609

EP - 619

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 6

ER -